The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatitis A Vaccine Market Research Report 2024
Synopsis
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
The global Hepatitis A Vaccine market was valued at US$ 705.8 million in 2023 and is anticipated to reach US$ 840.5 million by 2030, witnessing a CAGR of 2.2% during the forecast period 2024-2030.
Global hepatitis a vaccine key players include GSK, Merck, Sanofi, etc. Global top 5 manufacturers hold a share over 80%.
Asia-Pacific is the largest market, with a share over 35%, followed by North America and Europe , both have a share over 55 percent.
In terms of product, inactivated vaccine is the largest segment, with a share about 85%. And in terms of application, the largest application is government institution, followed by private sector, etc.
This report aims to provide a comprehensive presentation of the global market for Hepatitis A Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis A Vaccine.
Report Scope
The Hepatitis A Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis A Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis A Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Sanofi
Sinovac
Zhejiang Pukang
Changchun Institute of Biological
KM Biologics
IMBCAMS
Convac
Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Segment by Application
Government Institution
Private Sector
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatitis A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatitis A Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
The global Hepatitis A Vaccine market was valued at US$ 705.8 million in 2023 and is anticipated to reach US$ 840.5 million by 2030, witnessing a CAGR of 2.2% during the forecast period 2024-2030.
Global hepatitis a vaccine key players include GSK, Merck, Sanofi, etc. Global top 5 manufacturers hold a share over 80%.
Asia-Pacific is the largest market, with a share over 35%, followed by North America and Europe , both have a share over 55 percent.
In terms of product, inactivated vaccine is the largest segment, with a share about 85%. And in terms of application, the largest application is government institution, followed by private sector, etc.
This report aims to provide a comprehensive presentation of the global market for Hepatitis A Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis A Vaccine.
Report Scope
The Hepatitis A Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis A Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis A Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Sanofi
Sinovac
Zhejiang Pukang
Changchun Institute of Biological
KM Biologics
IMBCAMS
Convac
Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Segment by Application
Government Institution
Private Sector
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatitis A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatitis A Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Hepatitis A Vaccine Market Overview
1.1 Product Overview and Scope of Hepatitis A Vaccine
1.2 Hepatitis A Vaccine Segment by Type
1.2.1 Global Hepatitis A Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Inactivated Vaccine
1.2.3 Live Attenuated Vaccine
1.3 Hepatitis A Vaccine Segment by Application
1.3.1 Global Hepatitis A Vaccine Market Value by Application: (2024-2030)
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Other
1.4 Global Hepatitis A Vaccine Market Size Estimates and Forecasts
1.4.1 Global Hepatitis A Vaccine Revenue 2019-2030
1.4.2 Global Hepatitis A Vaccine Sales 2019-2030
1.4.3 Global Hepatitis A Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hepatitis A Vaccine Market Competition by Manufacturers
2.1 Global Hepatitis A Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hepatitis A Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hepatitis A Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Hepatitis A Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatitis A Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatitis A Vaccine, Product Type & Application
2.7 Hepatitis A Vaccine Market Competitive Situation and Trends
2.7.1 Hepatitis A Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hepatitis A Vaccine Players Market Share by Revenue
2.7.3 Global Hepatitis A Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hepatitis A Vaccine Retrospective Market Scenario by Region
3.1 Global Hepatitis A Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hepatitis A Vaccine Global Hepatitis A Vaccine Sales by Region: 2019-2030
3.2.1 Global Hepatitis A Vaccine Sales by Region: 2019-2024
3.2.2 Global Hepatitis A Vaccine Sales by Region: 2025-2030
3.3 Global Hepatitis A Vaccine Global Hepatitis A Vaccine Revenue by Region: 2019-2030
3.3.1 Global Hepatitis A Vaccine Revenue by Region: 2019-2024
3.3.2 Global Hepatitis A Vaccine Revenue by Region: 2025-2030
3.4 North America Hepatitis A Vaccine Market Facts & Figures by Country
3.4.1 North America Hepatitis A Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hepatitis A Vaccine Sales by Country (2019-2030)
3.4.3 North America Hepatitis A Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatitis A Vaccine Market Facts & Figures by Country
3.5.1 Europe Hepatitis A Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hepatitis A Vaccine Sales by Country (2019-2030)
3.5.3 Europe Hepatitis A Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis A Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Hepatitis A Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hepatitis A Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Hepatitis A Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatitis A Vaccine Market Facts & Figures by Country
3.7.1 Latin America Hepatitis A Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hepatitis A Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Hepatitis A Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatitis A Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis A Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hepatitis A Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hepatitis A Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hepatitis A Vaccine Sales by Type (2019-2030)
4.1.1 Global Hepatitis A Vaccine Sales by Type (2019-2024)
4.1.2 Global Hepatitis A Vaccine Sales by Type (2025-2030)
4.1.3 Global Hepatitis A Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Hepatitis A Vaccine Revenue by Type (2019-2030)
4.2.1 Global Hepatitis A Vaccine Revenue by Type (2019-2024)
4.2.2 Global Hepatitis A Vaccine Revenue by Type (2025-2030)
4.2.3 Global Hepatitis A Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Hepatitis A Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hepatitis A Vaccine Sales by Application (2019-2030)
5.1.1 Global Hepatitis A Vaccine Sales by Application (2019-2024)
5.1.2 Global Hepatitis A Vaccine Sales by Application (2025-2030)
5.1.3 Global Hepatitis A Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Hepatitis A Vaccine Revenue by Application (2019-2030)
5.2.1 Global Hepatitis A Vaccine Revenue by Application (2019-2024)
5.2.2 Global Hepatitis A Vaccine Revenue by Application (2025-2030)
5.2.3 Global Hepatitis A Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Hepatitis A Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Hepatitis A Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Hepatitis A Vaccine Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Hepatitis A Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Sinovac
6.4.1 Sinovac Corporation Information
6.4.2 Sinovac Description and Business Overview
6.4.3 Sinovac Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sinovac Hepatitis A Vaccine Product Portfolio
6.4.5 Sinovac Recent Developments/Updates
6.5 Zhejiang Pukang
6.5.1 Zhejiang Pukang Corporation Information
6.5.2 Zhejiang Pukang Description and Business Overview
6.5.3 Zhejiang Pukang Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Zhejiang Pukang Hepatitis A Vaccine Product Portfolio
6.5.5 Zhejiang Pukang Recent Developments/Updates
6.6 Changchun Institute of Biological
6.6.1 Changchun Institute of Biological Corporation Information
6.6.2 Changchun Institute of Biological Description and Business Overview
6.6.3 Changchun Institute of Biological Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Changchun Institute of Biological Hepatitis A Vaccine Product Portfolio
6.6.5 Changchun Institute of Biological Recent Developments/Updates
6.7 KM Biologics
6.6.1 KM Biologics Corporation Information
6.6.2 KM Biologics Description and Business Overview
6.6.3 KM Biologics Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 KM Biologics Hepatitis A Vaccine Product Portfolio
6.7.5 KM Biologics Recent Developments/Updates
6.8 IMBCAMS
6.8.1 IMBCAMS Corporation Information
6.8.2 IMBCAMS Description and Business Overview
6.8.3 IMBCAMS Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 IMBCAMS Hepatitis A Vaccine Product Portfolio
6.8.5 IMBCAMS Recent Developments/Updates
6.9 Convac
6.9.1 Convac Corporation Information
6.9.2 Convac Description and Business Overview
6.9.3 Convac Hepatitis A Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Convac Hepatitis A Vaccine Product Portfolio
6.9.5 Convac Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis A Vaccine Industry Chain Analysis
7.2 Hepatitis A Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis A Vaccine Production Mode & Process
7.4 Hepatitis A Vaccine Sales and Marketing
7.4.1 Hepatitis A Vaccine Sales Channels
7.4.2 Hepatitis A Vaccine Distributors
7.5 Hepatitis A Vaccine Customers
8 Hepatitis A Vaccine Market Dynamics
8.1 Hepatitis A Vaccine Industry Trends
8.2 Hepatitis A Vaccine Market Drivers
8.3 Hepatitis A Vaccine Market Challenges
8.4 Hepatitis A Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
